Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...
How do we “name” a cell and assign its identity? How do we know that we are all talking about the same cells? How do we agree on what it takes to confidently correlate previous with current research ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results